One of the key topics arising out of probably the hottest session (lung cancer clinical trials plenary) at AACR last week was tumour mutation burden (TMB).
An important question to be addressed was whether or not the nivolumab plus ipilimumab combination from the CheckMate–227 study will be useful in previously untreated non-small cell lung cancer (NSCLC) patients with a high TMB?
There are a number of questions that occurred to us that need careful consideration:
- Is TMB ready for prime time?
- What are the challenges and issues involved?
- How useful are the data from CheckMate–227 and CheckMate–568?
- Where are we going next?
To find out more, we had some fascination discussions at AACR with two up and coming young researchers from industry (Dr David Fabrizio of Foundation Medicine) and academia (Dr Nicky McGranahan from UCL in London), who are both experts intimately involved in measuring TMB.
What did they had to say and what does it all mean?
Their candid answers may well surprise a few people…